Bulb shape with provider and patient hands

Invitae Digital Health

Illuminating more human insights

A digital health platform that empowers individuals to unlock the value of genomics.

  • A HIPAA-compliant, secure platform that connects the dots

    In precision medicine, there is a constellation of decisions and actions associated with managing, delivering and receiving care at important decision points along a patient’s health journey. Invitae Digital Health allows you to intuitively and efficiently connect the dots, see the big picture.

    By leveraging the latest medical, genomic and technological advancements, Invitae Digital Health empowers you with actionable information for taking on some of healthcare’s most difficult problems—from cancer to cardiovascular disease, reproductive health to medication optimization.

Seamless care coordination pathway

  • Streamline coordination of clinically-appropriate preventive services such as MRIs, prophylactic surgeries and in-person and virtual care visits1-3
  • Enhance patient care by following medical management recommendations1-3
  • Reduce healthcare costs by reducing hospitalizations and emergency room visits4,5
  • Reduce spending on ineffective medications and potentially prevent complications6
  • Identify individuals at risk and provide clinical management recommendations intended to improve clinical outcomes
  • Close care gaps and matching each patient to personalized management, helping you provide precision medicine
  • Get clinical support at important decision points, powered by evidence-based, clinical guidance in line with medical guidelines
  • Evolve from reactive to proactive medicine
  • Access to medical advancements and personalized care
  • Gain an enhanced experience, even before an office visit, with consistent, up-to-date education resources and tools
  • Identify family members who may also be at-risk based on their genetics
Personalized Genetic Insights Graphic on a Computer and Phone – Invitae Corporation

The platform

Our dashboard combines real-world data, imaging and pathology reports, treatment selections, and patient-reported outcomes to help you monitor population health.

Dr. Peter Beitsch

As a busy breast cancer surgeon, it’s ideal to sign on to a single platform to conduct a risk assessment for all of my patients, order genetic tests, and interpret the results with management insights. That includes germline, somatic, liquid biopsy, and pharmacogenomic testing, all in one place. This one platform makes my clinic workflow so much easier, and the prompts make sure I don't forget anything while personalizing my patient care.”

- Peter Beitsch, M.D., Breast Surgical Oncologist, Research Director of iGAP Registry

NCCN=National Comprehensive Cancer Network

References
1. Daly MB, et al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(1):77–102.
2. Weiss JM, et al. NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2021. J Natl Compr Canc Netw. 2021;19(10):1122–1132.
3. NCCN Guidelines Prostate Cancer V.1.2022. NCCN. May 7, 2021. Accessed March 13, 2022. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459.
4. Brixner D, et al. The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. J Med Econ. 2016;19(3):213–228.
5. Elliot, LS, et al. Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial. PLOS ONE. 2017;12(2):e0170905.
6. Verbelen M, et al. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?. Pharmacogenomics J. 2017;17:395–402.